# Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment

> **NCT02370017** · PHASE2 · UNKNOWN · sponsor: **The Catholic University of Korea** · enrollment: 68 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** ANKL(Ex vivo-expanded NK cell enriched lymphocytes)

## Key facts

- **NCT ID:** NCT02370017
- **Lead sponsor:** The Catholic University of Korea
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2018-08
- **Final completion:** 2020-02
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2017-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02370017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02370017, "Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02370017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*